Top in endocrinology: Phthalates and menopause, #HealthEquityNow

A recent study suggests that phthalate exposure may contribute to sleep disruption among women during menopause. It was the top story in endocrinology last week.

Another top story was about a new initiative led by the American Diabetes Association (ADA) that aims to address health disparities exacerbated by the COVID-19 pandemic among people with diabetes, particularly those of color.

Read these and more stories in endocrinology below:

Phthalates may contribute to sleep disruption in menopause

Phthalate exposure may negatively affect sleep quality for midlife women, according to a study published in Menopause. Read more.

‘We need to actually do something’: ADA CEO unveils #HealthEquityNow initiative

Healio spoke with Tracey Brown, CEO of the ADA, about how the COVID-19 pandemic is worsening health disparities among people with diabetes, particularly people of color with diabetes, and a new initiative, #HealthEquityNow, designed to push for real change.

Growing evidence shows endocrine-disrupting chemicals drive obesity, infertility, diabetes

Endocrine-disrupting chemicals negatively affect a wide range of systems throughout the human body and have consequences at every life stage, and clinicians should counsel patients to try to reduce their exposure, according to researchers. Read more.

Sodium, potassium guidelines rarely met by adults with diabetes

Australian residents with diabetes are not meeting guidelines for dietary sodium and potassium and are not likely to change their intake over time, according to a study published in Nutrition & Diabetes. Read more.

Tips for managing foot disease in diabetes during COVID-19

Foot complications of diabetes typically require face-to-face consultations and treatment, presenting several unique challenges for clinicians during the COVID-19 pandemic. Read more.